Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia.
The aims of this study were to evaluate the emotional status and life quality of the patients with spasmodic dysphonia (SD) before and after botulinum toxin treatment, and to ascertain whether SD is a somatoform disorder. Ten patients with spasmodic dysphonia were injected unilaterally into the vocal cord with botulinum toxin. Before botulinum toxin treatment, two clinician's rating scales--Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS), and three self-rating psychometrics--Zung's Self-Rating Depression Scale (SDS), Life Quality Scale (GHQ/QL-12), and Symptom Distress Checklist (SCL-90) were applied. Self-rating scales were also administered in 20 matched normal controls. The patients were reevaluated 1 month after botulinum toxin treatment. The Clinical Global Impression Scale (CGI) was also rated by the patients themselves and a speech pathologist. The mean scores of SD patients were significantly higher than that of controls in SDS, and subscales of somatization, obsessive-compulsive symptoms, depression, anxiety, and psychoticism in SCL-90. The mean score of GHQ/QL-12 was significantly higher in the control group. The scores of HDRS, SDS, GHQ/QL-12 and subscales of somatization, depression, and anxiety in SCL-90 showed significant improvement after botulinum treatment. In CGI, seven patients were rated as improved by patients themselves and the speech pathologist. The patients with SD had more anxiety, depression and somatization symptoms, and poor life quality than normal controls. Their emotional status and life quality improved after botulinum toxin treatment. The results suggest that the emotional symptoms of patients with SD are mainly secondary to voice disorder.
Liu
C Y
CY
Department of Psychiatry, Chang Gung University School of Medicine, Taoyuan, Taiwan, R.O.C.
Yu
J M
JM
Wang
N M
NM
Chen
R S
RS
Chang
H C
HC
Li
H Y
HY
Tsai
C H
CH
Yang
Y Y
YY
Lu
C S
CS
D000328:Adult; D000368:Aged; D001007:Anxiety / Q000209:etiology; D001905:Botulinum Toxins / Q000627:therapeutic use; D016022:Case-Control Studies; D003863:Depression / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use; D011788:Quality of Life; D013001:Somatoform Disorders / Q000145:classification / Q000209:etiology; D013035:Spasm / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D013315:Stress, Psychological / Q000209:etiology*; D016896:Treatment Outcome; D014832:Voice Disorders / Q000150:complications* / Q000188:drug therapy / Q000523:psychology
D009465:Neuromuscular Agents; D001905:Botulinum Toxins